1-3 of 3
Jin Wu
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Safety, Efficacy, and Biomarker Analysis of Toripalimab in Patients with Previously Treated Advanced Urothelial Carcinoma: Results from a Multicenter Phase II Trial POLARIS-03

Xinan Sheng, Haige Chen, Bin Hu, Xudong Yao, Ziling Liu, Xin Yao, Hongqian Guo, Yi Hu, Zhigang Ji, Hong Luo, Benkang Shi, Jiyan Liu, Jin Wu, FangJian Zhou, Zhisong He, Jinhai Fan, Weifeng Wang, Hui Feng, Sheng Yao, Patricia Keegan, Yiran Huang, Jun Guo
Journal: Clinical Cancer Research
Clin Cancer Res (2022) 28 (3): 489–497.
https://doi.org/10.1158/1078-0432.CCR-21-2210
Published: 01 February 2022
View article titled, Safety, Efficacy, and Biomarker Analysis of Toripalimab in Patients with Previously Treated Advanced Urothelial Carcinoma: Results from a Multicenter Phase II Trial POLARIS-03
Open the PDF for Safety, Efficacy, and Biomarker Analysis of Toripalimab in Patients with Previously Treated Advanced Urothelial Carcinoma: Results from a Multicenter Phase II Trial POLARIS-03 in another window
Includes: Supplementary data
Journal Articles

Routine-Dose and High-Dose Icotinib in Patients with Advanced Non–Small Cell Lung Cancer Harboring EGFR Exon 21-L858R Mutation: the Randomized, Phase II, INCREASE Trial

Xi Li, Li Zhang, Da Jiang, Yan Wang, Aimin Zang, Cuimin Ding, Min Zhao, Wuyun Su, Yan Zhang, Diansheng Zhong, Jin Wu, Cuiying Zhang, Guangyu An, Xingsheng Hu, Gang Cheng, Huaqing Wang, Yongqun Li, Xiaohui He, Junli Liu, Li Liang, Lieming Ding, Li Mao, Shucai Zhang
Journal: Clinical Cancer Research
Series: Author Choice
Clin Cancer Res (2020) 26 (13): 3162–3171.
https://doi.org/10.1158/1078-0432.CCR-19-3064
Published: 01 July 2020
View article titled, Routine-Dose and High-Dose Icotinib in Patients with Advanced Non–Small Cell Lung Cancer Harboring EGFR Exon 21-L858R Mutation: the Randomized, Phase II, INCREASE Trial
Open the PDF for Routine-Dose and High-Dose Icotinib in Patients with Advanced Non–Small Cell Lung Cancer Harboring EGFR Exon 21-L858R Mutation: the Randomized, Phase II, INCREASE Trial in another window
Includes: Supplementary data
Journal Articles

Abstract B38: Trastuzumab-induced recruitment of Csk-homologous kinase (CHK) to ErbB2 receptor is associated with ErbB2-Y1248 phosphorylation and ErbB2 degradation to mediate cell growth inhibition

Milos Dokmanovic, Yun Wu, Yi Shen, Jieqing Chen, Dianne S. Hirsch, Wen Jin Wu
Journal: Clinical Cancer Research
Clin Cancer Res (2015) 21 (4_Supplement): B38.
https://doi.org/10.1158/1557-3265.PMS14-B38
Published: 13 February 2015
View article titled, Abstract B38: Trastuzumab-induced recruitment of Csk-homologous kinase (CHK) to ErbB2 receptor is associated with ErbB2-Y1248 phosphorylation and ErbB2 degradation to mediate cell growth inhibition